Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC ☆
Titel:
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC ☆
Auteur:
Mok, T.S.K. Lopes, G. Cho, B.C. Kowalski, D.M. Kasahara, K. Wu, Y.-L. de Castro Jr., G. Turna, H.Z. Cristescu, R. Aurora-Garg, D. Loboda, A. Lunceford, J. Kobie, J. Ayers, M. Pietanza, M.C. Piperdi, B. Herbst, R.S.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 34 () nr. 4 pagina's 377-388
Jaar:
2023
Inhoud:
Uitgever:
Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., The Author(s)